- Stocks /
- AFT Pharmaceuticals Ltd (ASX: AFP) /
AFT Pharmaceuticals Ltd (ASX: AFP) Share Price and News
Price
$2.39
Movement
0.00 (0.0)
As at 22 Aug - Closed (20 mins delayed)
52 Week Range
$2.15 - $3.16
1 Year Return
-16.72%
AFT Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Earnings Yield
4.09%
Franking
-
Dividend per share
0.01
Year To Date Return
-3.49%
Shares Outstanding
104.87 million
Earnings per share
0.110
Share Price
$2.39
Day Change
0.00 (0.0)
52 Week Range
$2.15 - $3.16
Yesterday's Close
$2.39
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
1,352
Turnover
$0
As at 22 Aug - Closed
AFT Pharmaceuticals Ltd (ASX: AFP)
Latest News

Healthcare Shares
75% upside: Broker tips two ASX healthcare shares
| Aaron Bell

Healthcare Shares
What's with the AFT Pharmaceuticals (ASX:AFP) share price today?
| Lucas Radbourne

Healthcare Shares
Why the AFT Pharmaceuticals (ASX:AFP) share price is in focus
| Ken Hall
Share Market News
Why the AFP Pharmaceuticals (ASX:AFP) share price is marching higher
| Aaron Teboneras
Coronavirus News
Coronavirus: ASX pharmacy networks report surge in demand
| Nikhil Gangaram
Coronavirus News
Are ASX pharmaceutical shares a bargain buy right now?
| Nikhil Gangaram
Share Gainers
Why the AFT Pharmaceuticals share price is up 55% since April
| Ken Hall
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
19 Jun 2024 | $0.0098 | 0.00% | Final | 04 Jul 2024 |
16 Jun 2023 | $0.0069 | 0.00% | Final | 04 Jul 2023 |
AFP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
4th Aug 2025 2025-08-04T12:44:22 | Results of 2025 Annual Shareholder Meeting | YesNo | 12:44pm | 1 | 149k |
1st Aug 2025 2025-08-01T07:30:51 | AFT ASM Presentation | YesNo | 7:30am | 30 | 4.3M |
1st Aug 2025 2025-08-01T07:30:41 | AFT ASM Chairs Speech | YesNo | 7:30am | 4 | 81k |
1st Aug 2025 2025-08-01T07:30:26 | AFT ASM Release | YesNo | 7:30am | 2 | 119k |
4th Jul 2025 2025-07-04T07:30:27 | Disclosure of Directors and Senior Managers Relevant Interes | YesNo | 7:30am | 2 | 528k |
1st Jul 2025 2025-07-01T07:31:05 | June Quarter FY 2026 Investor Update | YesNo | 7:31am | 4 | 173k |
27th Jun 2025 2025-06-27T07:31:06 | Disclosure of Directors and Senior Managers Relevant Interes | YesNo | 7:31am | 2 | 502k |
27th Jun 2025 2025-06-27T07:30:56 | Notice of Annual Meeting of Shareholders 2025 | YesNo | 7:30am | 3 | 162k |
24th Jun 2025 2025-06-24T15:04:31 | Update - Dividend/Distribution - AFP | YesNo | 3:04pm | 4 | 14k |
24th Jun 2025 2025-06-24T10:00:09 | Update - Dividend/Distribution - AFP | YesNo | 10:00am | 4 | 14k |
About AFT Pharmaceuticals Ltd
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
AFP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
21 Aug 2025 | $2.39 | $-0.06 | -2.45% | 700 | $2.40 | $2.40 | $2.39 |
19 Aug 2025 | $2.45 | $0.00 | 0.00% | 1,350 | $2.45 | $2.45 | $2.45 |
18 Aug 2025 | $2.45 | $0.06 | 2.51% | 373 | $2.45 | $2.45 | $2.45 |
15 Aug 2025 | $2.39 | $0.04 | 1.70% | 708 | $2.35 | $2.39 | $2.35 |
14 Aug 2025 | $2.35 | $-0.10 | -4.08% | 3,161 | $2.45 | $2.45 | $2.35 |
13 Aug 2025 | $2.45 | $0.00 | 0.00% | 2,500 | $2.45 | $2.45 | $2.45 |
12 Aug 2025 | $2.45 | $0.00 | 0.00% | 476 | $2.44 | $2.45 | $2.44 |
11 Aug 2025 | $2.45 | $0.05 | 2.08% | 551 | $2.45 | $2.45 | $2.45 |
08 Aug 2025 | $2.40 | $-0.11 | -4.38% | 1,805 | $2.41 | $2.41 | $2.40 |
07 Aug 2025 | $2.51 | $0.06 | 2.45% | 1,260 | $2.52 | $2.52 | $2.51 |
06 Aug 2025 | $2.45 | $0.05 | 2.08% | 4,000 | $2.45 | $2.45 | $2.45 |
31 Jul 2025 | $2.40 | $-0.09 | -3.61% | 2,881 | $2.49 | $2.49 | $2.40 |
30 Jul 2025 | $2.49 | $-0.07 | -2.73% | 622 | $2.57 | $2.57 | $2.49 |
29 Jul 2025 | $2.56 | $-0.03 | -1.16% | 4,143 | $2.60 | $2.61 | $2.50 |
28 Jul 2025 | $2.59 | $0.11 | 4.44% | 2,379 | $2.50 | $2.59 | $2.50 |
25 Jul 2025 | $2.48 | $0.02 | 0.81% | 460 | $2.48 | $2.48 | $2.48 |
24 Jul 2025 | $2.46 | $-0.07 | -2.77% | 1,250 | $2.46 | $2.46 | $2.46 |
23 Jul 2025 | $2.53 | $-0.01 | -0.39% | 2,187 | $2.53 | $2.54 | $2.53 |
22 Jul 2025 | $2.54 | $0.09 | 3.67% | 299 | $2.50 | $2.54 | $2.50 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
27 Nov 2024 | Hartley Atkinson | Buy | 45 | $126 |
On-market trade. NZD$, As per announcement on 02-12-2024
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Andrew Michael Lane | Non-Executive Director | Sep 2023 |
Mr Lane has more than 30 years of experience of leadership in the global pharmaceuticals industry with expertise across a broad range of disciplines including finance, manufacturing, sales, marketing, and strategy. Most recently he was Global President of Abbott Laboratories Pharma Division where he led a multi-billion-dollar operation that had 30 manufacturing plants, 12 Innovation and Development sites and 40,000 staff covering more than 100 countries. Before that he was Vice President of Takeda, Asia Pacific, where he managed the company's operations in 12 countries, which included three factories and 2,000 staff. He has also held senior roles with multi-national pharmaceutical companies Nycomed, DKSH, Novartis, and Sandoz.
|
Mr David Mark Flacks | Non-Executive ChairmanNon-Executive Director | Jun 2015 |
Mr Flacks has several governance roles and has been chair of AFT since the IPO in 2015. David is also chair of the Suncorp New Zealand group of companies and is a Director of Todd Corporation and several environmentally focused pro bono organizations. He is a director of boutique corporate law firm Flacks & Wong. David was for many years a Senior Corporate Partner at Bell Gully and was General Counsel and Company Secretary of Carter Holt Harvey during the 1990's.
|
Ms Marree Atkinson | Chief of Staff Co-founderManaging Director | Sep 2012 |
Ms Atkinson's role as Chief of Staff sees her involved in the day-to-today running of AFT's head office including managing staffing requirements and special projects involving AFT's head and affiliate offices.
|
Mr Hartley Atkinson | FounderChief Executive OfficerExecutive Director | Sep 1997 |
Mr Atkinson before founding AFT, Hartley worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, Hartley was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. Hartley is the author of several scientific publications, and his work has been published in the New England Journal of Medicine.
|
Dr Ted Witek | Non-Executive Director | Jan 2021 |
Mr Witek served Boehringer Ingelheim Pharmaceuticals for nearly 25 years in clinical research and leadership roles, including CEO of its Canadian and Portuguese operations. Ted was also Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva and on the Board of Directors of Canada's Research-Based Pharmaceutical Companies.
|
Ms Allison Yorston | Non-Executive Director | Nov 2024 |
Ms Yorston brings to AFT more than 20 years of blue-chip fast-moving consumer goods, telecommunications and retail marketing experience gained across Australia and New Zealand at senior management and C-suite levels. She has managed brand turnarounds and grown and developed marketing teams to deliver share gains in competitive markets and is experienced at managing multi-brand portfolios including both product and corporate brands. She is currently Director of Marketing at Griffins Snacks and is a former Director of the Australian Beverages Council and a former Chief Marketing Officer at Suntory Beverage & Food Oceania. Prior to Suntory she held senior marketing roles at Vodafone, Fonterra and Sanitarium.
|
Mr Malcolm Tubby | Chief Financial OfficerCompany Secretary |
-
|
|
Malcolm Tubby | Chief Financial OfficerCompany Secretary |
-
|
|
Ioana Stanescu | Chief Scientific Officer |
-
|
|
Louise Clayton | Director International Business |
-
|
|
Scott Crawford | General Manager Promoted Products |
-
|
|
Murray Keith | Group Marketing Manager |
-
|
|
Vladimir Ilievski | Regulatory Affairs Manager |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hartley Atkinson & Colin Mckay | 72,041,741 | 68.70% |
Accident Compensation Corporation NZCSD | 7,498,335 | 7.15% |
Forsyth Barr Custodians Limited | 5,315,534 | 5.07% |
HSBC Nominees A/C NZ Superannuation Fund Nominees Limited - NZCSD | 1,688,572 | 1.61% |
BNP Paribas Nominees (NZ) Limited NZCSD | 1,096,790 | 1.05% |
BNP Paribas Nominees (NZ) Limited NZCSD i | 1,046,390 | 1.00% |
New Zealand Depository Nominee Limited | 877,928 | 0.84% |
Hama Holdings Limited1 | 867,826 | 0.83% |
MMC Queen Street Nominees Limited Acf Salt Long Short Fund NZCSD | 768,123 | 0.73% |
Forsyth Barr Custodians Limited i | 506,409 | 0.48% |
FNZ Custodians Limited | 495,601 | 0.47% |
MMC Limited NZCSD | 420,554 | 0.40% |
Custodial Services Limited | 362,369 | 0.35% |
Garrett Smythe Limited | 336,612 | 0.32% |
JP Morgan Nominees Australia Limited | 300,000 | 0.29% |
Joeri Yvonne Jozef Sels | 212,832 | 0.20% |
Jbwere (Nz) Nominees Limited | 206,990 | 0.20% |
FNZ Custodians Limited i | 193,348 | 0.18% |
MMC Queen Street Nominees Ltd Acf Salt Funds Management | 189,000 | 0.18% |
David Mark Flacks & Adina Rita Betty Halpern | 158,764 | 0.15% |